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ABSTRACT
Background: Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver
dysfunction in patients with or without previous liver injury, and this is not well discussed in
the previous literature.
Methods: A total sample of 202 patients were retrospectively reviewed at the University of
Missouri, Kansas City, from the year 2015 to 2018 based on predefined selection criteria.
Inclusion criteria involved patients with dyslipidemia, with or without PCSK-9 inhibitors, liver
function tests and lipid profile at baseline and at a mean of 6-month follow-up. The variables,
including age, gender, and confounding factors like other medications (statin, oral antidia-
betic, and antihypertensive) induced, or chronic secondary liver diseases causing liver injury
were taken into consideration. Exclusion criteria included patients without dyslipidemia.
Results: The mean age of the study population was 64 ± 11 years (63% males and 37%
females). The lipid profile including triglyceride and cholesterol levels during 6-month follow-
up visit showed a mean of 184 ± 260 and 163 ± 50 mg/dL as compared to that at baseline of
227 ± 603 and 181 ± 70 mg/dL, respectively. In terms of clinical efficacy, a 6-month follows-up
showed a drop in triglyceride and cholesterol levels by 38 and 15 mg/dL, respectively. A liver
function test at 6 months in patients taking PCSK-9 inhibitors showed an increase in alanine
transaminase (ALT) and aspartate transaminase (AST) by 5.8 mg/dL (p = 0.037) and 6.2 mg/dL
(p = 0.008), respectively, from baseline values.
Conclusion: PCSK-9 inhibitors should be used cautiously with a follow-up liver function test.
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1. Introduction
Heart disease is one of the major causes of mortality in
bothmales and females. The statistical data provided by
the Center for Disease Control state that 610,000 people
in the USA die of heart disease every year. This consti-
tutes one out of every four deaths per year among
Americans. Coronary artery disease (CAD) is a major
contributor to this mortality rate of 370,000 per year [1].
CAD is caused by a variety of modifiable and non-
modifiable risk factors. Dyslipidemia is the most sig-
nificantmodifiable risk factor involved in the pathogen-
esis of heart disease, including CAD. Dyslipidemia is
defined as having abnormal lipid levels in the blood,
which can include elevated total cholesterol, elevated
low-density lipoprotein-cholesterol (LDL-C) and/or
decreased levels of high-density lipoprotein (HDL) cho-
lesterol. An estimated 53% (105,3000) of US adults had
lipid abnormalities [2]. LDL is the single most major
modifiable risk factor for atherogenesis. Therefore,
reducing LDL-C is very important for cardiovascular
disease prevention [3].
For treatment of hypercholesterolemia, there are
several approaches, including non-pharmacological
and pharmacological, to lower LDL. Some of the non-
pharmacological approaches include a diet consisting of
vegetables, fruits and low saturated fats; weight loss; and
exercise. The pharmacological approach includes sta-
tins, niacin, ezetimibe, bile acid sequestrants, fibrates,
fish oil, garlic and plant sterols. Proprotein convertase
subtilisin/Kexin type-9 inhibitors (PCSK-9), a new
medication for hyperlipidemia, slow the progression
of atherosclerosis and prevent death in CAD with an
effect as 70% that of a statin. Statin is a prototype of
cholesterol-lowering medications and famous in CAD
prevention and progression. Statins lower LDL by inhi-
biting the synthesis of LDL, but a new PCSK-9 inhibitor
flipped the coin by causing more removal of LDL from
blood rather than decreasing synthesis with a similar
anti-oxidative effect on the vessels [4–7]. The Food and
Drug Administration (FDA) has approved two PCSK-9
inhibitors including alirocumab and evolocumab for
treatment of hyperlipidemia [8]. PCSK-9 inhibitors
are considered as an addition in treatment regimen in
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dyslipidemia unresponsive to maximum dose of statins.
In addition to therapeutic role, PCSK-9 inhibitors also
cause hepatocyte damage, presenting as elevation in
serum transaminases. PCSK-9 can enhance the liver
injury in patients with risk factor of liver injury like
hepatic steatosis [9]. Limited studies have been done
discussing clinical efficacy and side effect profile of
PCSK-9 inhibitors in hepatic steatosis/underlying liver
injury. Our study investigated PCSK-9 inhibitors' effect
on liver in patients with underlying liver dysfunction.
2. Methods
2.1. Study population
Our study population consisted of hyperlipidemia
patients followed at the University of Missouri,
Kansas City, from 2015 to 2018. The study protocol
strictly follows the Helsinki Ethical guidelines for
animals and humans as reflected by the Institutional
Review Board of the University of Missouri, Kansas
City. The study strictly maintains the confidentiality
of the reviewed data of the participants.
This retrospective study included a sample of 202
patients based on our selection criteria. Inclusion criteria
involved patients with hyperlipidemia/dyslipidemia,
with/without PCSK-9 inhibitors, liver injury markers
for toxic insult (ALT and AST) and lipid profile (serum
cholesterol and triglyceride [TG]) at baseline and at
a mean of 6-month follow-up. All the study participants
had a stable liver synthetic function (albumin and PT/
PTT).When study participants were initiated on PCSK-9
inhibitor, either they were not on statins or sulfonylureas,
or they have chronic stable normal baseline LFT with no
prior insult, or if the patients were taking statin or
sulfonylureas, then their doses have not been changed
recently to decrease the confounding and to link the
effect of liver dysfunction likely secondary to PCSK-9
inhibitors. Exclusion criteria included patients with no
history of hyperlipidemia. The demographic variables
including age and gender were taken into consideration.
Among the study population, the following comorbid-
ities were studied: diabetes mellitus, hypertension, con-
gestive heart failure, kidney disease, liver disease and
smoking status. Patients who were taking statins or sul-
fonylureas and had any previous abnormal LFTs were
excluded from our study. The medications used for these
comorbidities causing abnormal liver function test were
studied to remove confounding factors; these medica-
tions include antiplatelet agents, antihypertensive agents,
insulin, oral hypoglycemic agents and PCSK-9 inhibitors.
2.2. Data collection and analysis
The demographic and clinical characteristics of the
included patients were taken into account. The clinical
data included liver function tests (ALT and AST) and
lipid profile (serum cholesterol and TG) at the baseline
and a mean 6-month duration. Continuous variables
were compared using the independent t-test and nom-
inal variables by using the χ2 and Fisher’s exact test
using SPSS version 2.0. Values of p≤ 0.05 were consid-
ered significant. Continuous variables were compared
using the independent t-test and nominal variables by
using the χ2 and Fisher’s exact test using SPSS version
2.0. Values of p ≤ 0.05 were considered significant.
3. Results
The mean age of the included population was 64 ± 11
years (63% males and 37% females). The mean baseline
TGwas 227 ± 603mg/dL andmean cholesterol was 181±
70 mg/dL. The lipid profile at mean 6-month duration
showed TG and cholesterol levels of 184 ± 260 and 163 ±
50mg/dL, respectively. For the total study population, the
TG and cholesterol levels drop from baseline levels to 38
and 15 mg/dL, respectively. The baseline characteristics
of the patients in the two groups (no PCSK inhibitor and
on PCSK-9 inhibitor) were comparable; 51% of the total
patients have diabetes and 86% have hypertension
(HTN); and only 15% of the diabetic and 17% of the
HTN groups were on PCSK-9 inhibitors. All patients
with CHF (30%), kidney disease (20%) and liver disease
(8%) belonged to the non-PCSK-9 group. Most patients
with smoking history were not in the PCSK-9 group
(Table 1).
Due to the abovementioned comorbidities, patients
were on medications described below, and none of the
medications had an effect on liver enzymes or lipid panel,
and hence, the confounding factors were excluded
(Table 2).
There was no significant association of PCSK-9 use
with the history of diabetes (p = 0.16) and HTN (p =
0.33). A moderately significant association of smoking
with PCSK-9 use was determined (p = 0.00). There
were not enough CHF and kidney and liver disease
Table 1. Frequency of having chronic diseases in patients.
Comorbidities
Total
percent
No PCSK-9
inhibitors (%)
On PCSK-9
inhibitors (%)
DM 51 85 15
HTN 86 83 17
CHF 30 100 0
Kidney diseases (KD) 20 100 0
Liver diseases (LD) 8 100 0
Never smoker (NS) 63 72 28
Former smoker (FS) 31 98 2
Current smoker (CS) 5 100 0
Table 2. Frequency of medication use in all patients.
Medications Percent
Antiplatelets 63
Antihypertensive 75
Insulin 41
Oral antidiabetics 41
PCSK-9 inhibitors 19
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patients in the PCSK-9 group to determine the statis-
tical difference from the non-PCSK-9 group (Table 3).
The mean decrease in the TG levels with the
PCSK-9 use was found to be 17 mg/dL which was
ironically lower than the levels in the patients not on
PCSK-9 (42 mg/dL). This value was, however, not
statistically significant (p = 0.75). There was no sig-
nificant variance in the TG levels between the two
groups (Levene’s test p = 0.57). Patients with PCSK-9
use had a significant mean cholesterol fall of 61 mg/
dL compared to only 5 mg/dL fall with no use of the
drug (p = 0.00). There was a significant variability on
Levene’s test (p = 0.001); hence, a modified t-test
value was interpreted (Tables 4 and5).
To determine the safety of PCSK-9 inhibitor use,
we determined the baseline liver function tests in
both groups and compared them to the 6-month
levels. There was a mean increase of about 5.8 mg/
dL in the ALT and 6.2 mg/dL in the AST with the use
of PCSK-9 inhibitors (Table 6). None of the patients
in our sample had acute liver failure with AST/ALT
more than 10 times elevation from baseline and liver
synthetic function abnormality. Both ALT and AST
elevation was statistically significant, with a p-value of
0.037 and 0.008, respectively. The independent t-test
and Levene’s test values are shown in Table 7.
4. Discussion
The FDA approved two new cholesterol-lowering med-
ications named alirocumab and evolocumab for
patients with familial hypercholesterolemia or heavy
burden of atherosclerotic disease on cholesterol-
lowering diet and maximally tolerated statin dose [7].
There are numerous factors that affect the concentra-
tion of lipids in the blood. Some of these include diet-
ary intake, certain medications and medical conditions
such as hypothyroidism and genetic diseases including
familial hypercholesterolemia. All of these conditions
can expose the arteries to high levels of atherogenic
lipoproteins like LDL and can cause an increased risk
of a premature cardiovascular event [4].
A PCSK-9 is a proprotein convertase enzyme pri-
marily expressed in the liver, central nervous system
and kidneys. A PCSK-9 gene is located on the short
arm p32.3 of chromosome 1. A PCSK-9 enzyme is
secreted as a soluble enzyme [1,2,8]. Its major action
is to enhance LDL-receptor (LDL-R) recycling. PCSK-
9 inhibitors are antibodies involved in the regulation of
LDL-C levels by blocking the recycling of LDL-R [10].
A PCSK-9 antibody attaches with LDL-R and inhibits
clathrin-mediated receptor endocytosis and break-
down. A simplified version of the mechanism of action
of PCSK-9 inhibitors is shown in Figure 1.
PCSK-9: proprotein convertase subtilisin/Kexin
type-9; LDL-R: low-density lipoprotein receptor;
LDL-C: low-density lipoprotein cholesterol.
Other potential mechanisms of PCSK-9 inhibition
to control LDL-C include gene silencing including
antisense oligonucleotide, small interfering RNA
(siRNA), peptides that mimic PCSK-9 and small
molecule inhibitors of PCSK-9 [11]. A gain or loss
of function is also found in PCSK-9 gene mutations
[11]. A gain of function of PCSK-9 is due to missense
mutations and increases levels/affinity of PCSK-9.
A loss of function of PCSK-9 is due to non-sense
/missense mutations and decreases levels/affinity of
PCSK-9 [11].
In terms of efficacy of PCSK-9 inhibitor alirocu-
mab, a LONGTERM trial by Seidah et al., 2341
patients showed up to 61% of the improvement in
LDL-C levels with alirocumab [12]. There are
a variety of trials that showed persistent improvement
Table 3. Association of chronic diseases with the PCSK-9 use.
Associations Test Value df p-Value
Diabetes Mellitus (DM) and PCSK-9 inhibitors Pearson chi-square 1.8 1 0.16
HTN and PCSK-9 inhibitors Pearson chi-square 0.94 1 0.33
congestive heart failure (CHF) and PCSK-9 inhibitors None as PCSK-9 is constant
KD and PCSK-9 inhibitors None as PCSK-9 is constant
LD and PCSK-9 inhibitors None as PCSK-9 is constant
aSmoking and PCSK-9 inhibitors Pearson chi-square 22.29 2 0.00
aCramer’s v value was 0.33 (moderate association).
Table 5. t-Test analysis for mean differences in the lipid profile with the use of PCSK-9 inhibitors.
Analyte Levene’s test t-Test for equality of means
F Sig. t df p-Value Mean difference 95% confidence interval of the difference
TG 0.317 0.57 −0.31 198 0.75 −25.37 −183.71 132.95
Cholesterol 10.594 0.001 5.51 45.46 0.00 56.19 35.67 76.72
Table 4. Mean fall in lipid panel with the PCSK-9 inhibitor
use.
Group statistics
Difference PCSK-9 N Mean
Std.
deviation
Std. error of
mean
TG No 164 −42.99 479.0 37.41
Yes 36 −17.61 87.4 14.57
Cholesterol No 163 −5.77 45.91 3.59
Yes 36 −61.97 57.21 9.53
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of LDL-C and prevention of cardiovascular disease
with PCSK-9 inhibitors; these trials include double-
blinded ODYSSEY trials (CHOICE I/II, COMBO I/II,
OPTIONS I/II, FHI/II, HIGH FH, ALTERNATIVE
and MONO) [13,14]. Based on phase II/MENDEL
trial for evolocumab, an LDL reduction up to 60%
is seen with twice-monthly scheduled evolocumab
and statins. The major phase III trials of evolocumab
are in program PROFICIO (Program to reduce LDL-
C and cardiovascular outcomes following inhibition
of PCSK-9 in different populations) [15]. There are
14 trials included in this program to assess the effi-
cacy of evolocumab in combination with statins, and
almost all of these trials showed positive results in
lowering cholesterol and decreasing cardiovascular
mortality [14]. These 14 trials include LAPLACE-2,
YUKAWA-2, GAUSS-2, GAUSS-3, MENDEL-2,
RUTHERFORD-2, TAUSSIG, TESLA, TAUSSIG,
THOMAS-1/2, DESCARTES, FOURIER, OSLER-2
and GLAGOV trials [14]. PCSK-9 inhibitors not
only have shown to decrease LDL-C but also cause
a significant reduction in atheroma size, progression,
rupture and instability as shown by Global
Assessment of Plaque Regression with a PCSK-9
Antibody as Measured by Intravascular Ultrasound
(GLAGOV) trial [16]. Furthermore, PCSK-9 inhibi-
tors can reduce lipoprotein by 36% and TG by
12–31% and can cause a modest increase in HDL-
cholesterol by 5–9% [17,18]. PCSK-9 inhibitors
reduce LDL-C and TG in a dose-dependent fashion
and can reduce up to 70% and 31% of LDL-C and TG
levels, respectively [19–21]. Our study showed the
mean decrease in cholesterol level of 61 mg/dL
Table 7. t-Test for the mean differences in the liver enzymes with the use of PCSK-9 inhibitors.
Variables Levene’s test for equality of variances t-Test for equality of means
F Sig. t df p-Value Mean difference Confidence interval
ALT 0.04 0.83 −2.13 57.18 0.037 −11.99 −23.23 −0.75
AST 1.17 0.28 −2.66 199 0.008 −14.09 −24.50 −3.68
Figure 1. LDL-receptor endocytosis by combination with PCSK-9 and lysosome-induced damage to LDL-R. PCSK-9 inhibitors
inhibit the formation of PCSK-9 and LDL-R complex, preventing degradation of LDL leading to increased levels of LDL-R on cells
and enhanced LDL-C update.
Table 6. Mean differences in the liver enzymes with the use
of PCSK-9 inhibitors.
Difference
PCSK-9
inhibitors N Mean
Std.
deviation
Std. error of
mean
ALT No 164 −6.26 33.16 2.58
Yes 37 5.72 30.29 4.98
AST No 164 −7.95 28.15 2.19
Yes 37 6.13 32.56 5.35
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compared to only 5 mg/dL fall with no use of the
drug (p = 0.00), and mean drop of TG is 17 mg/dL as
compared to a level of 42 mg/dL for patients not on
PCSK with a non-statistically significant p-value
of 0.57.
Clinical benefits of PCSK-9 outweigh the side-
effect profile. PCSK-9 inhibitors can cause a variety
of side effects including neurocognitive side effects,
rhabdomyolysis, liver damage, new-onset diabetes
mellitus and risk of local allergy at the injection site
[22]. The literature review showed both neutral and
positive side effects on liver. A meta-analysis by
Guedeney et al. found no liver dysfunction in patients
taking PCSK-9 inhibitors [23]. Another study by
Theocharidou et al. reported that high intrahepatic
and serum concentration of PCSK-9 can enhance the
underlying liver damage, and use of PCSK-9 inhibi-
tors slows this damage through inhibition of PCSK-9
expression and insulin resistance [24]. Our study
found a negative side effect of PCSK-9 inhibitors on
liver; our results showed a mean increase in ALT and
AST of 5.8 mg/dL (p = 0.037) and 6.2 mg/dL (p =
0.008) on a 6-month follow-up as compared to base-
line, respectively.
5. Limitations
The side-effect profile varies from neutral, negative or
positive in the published literature. Our study failed
to show any clear temporal relationship of PCSK-
9-induced liver dysfunction (negative side-effect pro-
file) in patients with underlying liver disease. Our
study is limited due to small sample size and limited
use of PCSK-9 inhibitors due to cost; more large-scale
cohort and randomized clinical trials are necessary to
develop the follow-up of patients taking PCSK-9
inhibitors and to study the liver function tests in
these patients. Further limitations of our study are
that none of our patients had a long-term follow-up
to further characterize liver dysfunction to significant
liver dysfunction (ALT/AST >10 times elevated), syn-
thetic liver dysfunction or any acute liver failure.
Another caveat of our study is the failure to show
that transaminitis was transient or persistent due to
short follow-up and loss of follow-up.
6. Conclusion
Our study showed that PCSK-9 inhibitors can cause
abnormal LFTs. A follow-up with liver function test
should be done in patients taking PCSK-9 inhibitors.
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